
    
      Previous study showed that administration of rivaroxaban reduced expression of
      proinflammatory mediators in apolipoprotein E-deficient mice. However, it is unknown whether
      the anti-inflammatory markers are decreased in patients with atrial fibrillation receiving
      novel oral anticoagulants.
    
  